Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer

Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer

Introduction Tyrosine kinase inhibitors (TKIs) have significantly improved the progression-free survival (PFS) of metastatic non-small cell lung cancer (NSCLC) with oncogene mutations of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) compared with systemic therapy alone...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sadhna Kannan, Kumar Prabhash, Anil Tibdewal, JaiPrakash Agarwal, Naveen Mummudi, Vanita Noronha, Vijay Patil, Nilendu Purandare, Amit Janu, Rajiv Kaushal
Formato: article
Lenguaje:EN
Publicado: BMJ Publishing Group 2021
Materias:
Medicine
R
Acceso en línea:https://doaj.org/article/92f32865e1284db5868d83e018827764
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/92f32865e1284db5868d83e018827764

Ejemplares similares